Meeting
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
Authors
Xi Guo
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Xi Guo , Yuhong Zhou , Rongyuan Zhuang , Chenlu Zhang , Yang You , Wei Li , Zhiming Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11572)
DOI
10.1200/JCO.2023.41.16_suppl.11572
Abstract #
11572
Poster Bd #
506
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
First Author: Jie Liu
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Annual Meeting
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
First Author: Koichi Azuma
Poster
2024 ASCO Annual Meeting
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.
First Author: Pei Dong